Sign Up for a Free Account
  • Updated 11.03.2020
  • Released 07.06.1999
  • Expires For CME 11.03.2023



Historical note and terminology

Ropinirole is a second-generation dopamine agonist. Dopamine agonists were first used in patients with moderate or advanced Parkinson disease. There is now a tendency to introduce dopamine agonists in the first stages of the disease as an attempt to delay motor fluctuations. Although many dopamine agonists were developed, only 4 were marketed and are used extensively for the treatment of Parkinson disease: apomorphine, bromocriptine, lisuride, and pergolide. Ropinirole is 1 of 3 newer dopamine agonists; the other 2 are cabergoline and pramipexole. Ropinirole hydrochloride was developed as SKF-101468A and was shown to have antiparkinsonian effects in primate MPTP models of parkinsonism (06). The United States Food and Drug Administration approved it in 1997 for the treatment of Parkinson disease.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660